3 Penny Stocks With Profits That Still Look Mispriced

Central banks across Asia Pacific are signalling that interest rates may stay relatively firm as inflation expectations adjust to higher energy costs. That keeps borrowing expensive for many smaller companies that rely on fresh funding. Elite Penny Stocks focuses on stocks that already hold stronger balance sheets. This article highlights 3 ideas from the screener that stand out for investors hunting calculated high risk, high reward opportunities.

The three stocks in this article are just a starting sample from the Elite Penny Stocks idea, and the full screen surfaced 9 more companies with equally compelling balance sheet strength and growth narratives that are not covered here. To identify and analyze the highest conviction setups right now, go straight to the Elite Penny Stocks screener.

NeuPath Health (TSXV:NPTH)

Overview: NeuPath Health is a Canadian healthcare provider that runs a network of clinics in Ontario and Alberta focused on chronic pain, musculoskeletal and sports injuries, concussions and workplace health services. These clinics are supported by a broad group of specialist physicians and therapists. The company also supplies independent medical assessments to employers, insurers and legal practices through its wider network of healthcare providers.

Operations: NeuPath Health generates all of its approximately CA$89 million in revenue from medical services in Canada.

Market Cap: CA$34.3 million

NeuPath Health sits at the intersection of essential healthcare demand and penny stock pricing, which is why it surfaces in the Elite Penny Stocks screener. The stock trades at a steep discount to Simply Wall St’s estimate of fair value. The company has recently moved into profitability and analysts expect very strong earnings growth off this base, even though revenue growth projections are more modest. Recent results show higher revenue and a swing from loss to profit, which is important for a business carrying higher risk external borrowing and a low 1.4% ROE. Investors still need to weigh a recent one off loss and a relatively new management team. These factors make NeuPath a higher risk, higher potential reward idea rather than a defensive healthcare play.

NeuPath Health is shifting from loss to profit while its stock still trades at a steep discount. Get the full story behind that gap and how it ties to DCF valuation analysis for NeuPath Health

Build your own undervalued healthcare shortlist

NeuPath Health and the two other stocks in this article all came from a single screener, but the real edge comes when you create your own filters. Use our flexible Screener to blend metrics like valuation, balance sheet strength and risks, or start with any of our ready made Investing Ideas.

CEMATRIX (TSX:CEMX)

Overview: CEMATRIX is a Calgary based construction materials company that produces and installs cellular concrete across North America for infrastructure, industrial and commercial projects. Its lightweight, flowable concrete is used in applications such as road and runway bases, bridge approaches, retaining walls, tunnels and pipe grouting.

Operations: CEMATRIX generates about CA$53.8 million in revenue from supplying and placing cellular concrete, with roughly CA$11.8 million from Canada and CA$42 million from the United States.

Market Cap: CA$72.6 million

CEMATRIX stands out in the Elite Penny Stocks screener because it combines a growing order backlog, a focus on lower carbon building materials and a record of accretive acquisitions in a niche where scale and specialized equipment matter. Recent contract wins worth roughly CA$9.2 million and stronger Q2 2026 results indicate that demand for its cellular concrete is feeding through to both sales and profits. The stock trades well below Simply Wall St’s DCF estimate of fair value, yet investors still need to weigh lumpy project based revenue, heavy reliance on external borrowing and concentrated exposure to North American infrastructure spending.

CEMATRIX’s order book, lower carbon focus and acquisition track record sit against a stock that trades well below fair value. Get the full context in the DCF valuation analysis for CEMATRIX, including what could narrow that gap.

Cannara Biotech (TSX:LOVE)

Overview: Cannara Biotech is a Canadian cannabis company that grows, processes and sells indoor premium cannabis and derivative products under its TRIBAL, nugz and ORCHID CBD brands, while also earning income from real estate operations. It distributes mainly through wholesalers and online merchandisers, aiming to offer higher quality products at competitive price points.

Operations: Cannara Biotech generates about CA$112.8 million from Cannabis Operations and CA$3.9 million from Real Estate Operations, with all reported revenue of roughly CA$117.3 million coming from Canada.

Market Cap: CA$199.5 million

Cannara Biotech is a profitable, vertically integrated producer with about 20 consecutive quarters of positive adjusted EBITDA, growing cash flow and a balance sheet that supports continued investment in new grow rooms, brands and export capacity. At the same time, this is a sector where pricing pressure, flat retail sales in Canada and heavy reliance on Quebec market share could all limit how much value that extra capacity creates. Recent moves such as the Curaleaf export agreement, a buyback for up to roughly 2% of shares and new higher margin product collaborations indicate a company positioning for its next phase. The open question is how that mix of growth options and risks will be reflected in the stock over time.

Cannara Biotech’s cash flow, export ambitions and buyback plan point to a story that many investors may not have fully priced in yet. However, the real twist sits inside the analyst forecasts for Cannara Biotech

Seeking Fresh Alternatives Beyond These Picks

Markets move fast and the best breakout setups rarely stay under the radar for long. Scan fresh momentum and solid fundamentals before the crowd, while it matters. Get in early.

• Spot strong cash generators that still look overlooked by building a watchlist from the 10 high quality undervalued stocks before these quality stories get fully caught by the market.
• Follow long term structural themes by tracking companies in the 36 power grid technology and infrastructure stocks and stay on top of businesses tied to critical energy infrastructure upgrades.
• Explore resilient income ideas using the 4 dividend fortresses and keep an eye on higher yielding stocks that may appeal to investors seeking steadier cash returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com